The InTime Trial aims to assess the effects of the investigational drug, CT38, in terms of its safety and effectiveness in treating ME/CFS. There will be 18 people between 18 and 60 years of age enrolled in this study and participation will last up to approximately 4 months.
Who:
| Dr. Lucinda Bateman, Located in Salt Lake City, Utah at the Bateman-Horne Institute. |
When:
Ongoing
What:
A Clinical Trial for ME/CFS Patients: BHC is conducting a small interventional trial, to test the effectiveness of a new drug that may improve functioning and/or reduce the symptoms in ME/CFS patients. The drug has been shown to be safe in a Phase 1 trial in healthy humans.
Where:
Bateman-Horne Institute, Salt Lake City, Utah
How to Participate:
If you are interested in participating in this trial, please follow the link below and fill out the following form to check for eligibility:
https://redcap01.brisc.utah.edu/ccts/redcap/surveys/?s=MC4EAT4YNE
